Paul Glue

Research interests

Publications

• Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders

  Journal of Psychopharmacology · 2018 · 10.1177/0269881118762073

• Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression

  American Journal of Geriatric Psychiatry · 2017 · 10.1016/j.jagp.2017.06.007

• Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders

  Journal of Psychopharmacology · 2017 · 10.1177/0269881117705089

• Placebo‐controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression

  Acta Psychiatrica Scandinavica · 2016 · 10.1111/acps.12572

• Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis

  The International Journal of Neuropsychopharmacology · 2015 · 10.1093/ijnp/pyv124

• ‘Violence is Not Part of Our Job’: A Thematic Analysis of Psychiatric Mental Health Nurses’ Experiences of Patient Assaults from a New Zealand Perspective

  Issues in Mental Health Nursing · 2014 · 10.3109/01612840.2014.892552

• Pilot dose–response trial of i.v. ketamine in treatment-resistant depression

  The World Journal of Biological Psychiatry · 2014 · 10.3109/15622975.2014.922697

• Ketamine as a new treatment for depression: A review of its efficacy and adverse effects

  Australian & New Zealand Journal of Psychiatry · 2013 · 10.1177/0004867413486842

• Optimal treatment of social phobia: systematic review and meta-analysis

  Neuropsychiatric Disease and Treatment · 2012 · 10.2147/ndt.s23317

• Pregabalin for painful HIV neuropathy

  Neurology · 2010 · 10.1212/wnl.0b013e3181ccc6ef

• Meta-Analysis of Relapse Prevention Antidepressant Trials in Depressive Disorders

  Australian & New Zealand Journal of Psychiatry · 2010 · 10.3109/00048671003705441

• Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism

  The Journal of Clinical Pharmacology · 2010 · 10.1177/0091270010366445

• Model-based Drug Development

  Clinical Pharmacology & Therapeutics · 2007 · https://doi.org/10.1038/sj.clpt.6100235

• Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study

  Nephrology Dialysis Transplantation · 2001 · 10.1093/ndt/16.1.193

• Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data

  Clinical Pharmacology & Therapeutics · 2000 · https://doi.org/10.1067/mcp.2000.110973

• A Dose-Ranging Study of Pegylated Interferon Alfa-2b and Ribavirin in Chronic Hepatitis C

  Hepatology · 2000 · 10.1053/jhep.2000.16661

• Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C

  Therapeutic Drug Monitoring · 2000 · 10.1097/00007691-200010000-00010

• Pharmacokinetics and Absolute Bioavailability of Ribavirin in Healthy Volunteers as Determined by Stable-Isotope Methodology

  Antimicrobial Agents and Chemotherapy · 1999 · 10.1128/aac.43.10.2451

• Attenuation of the Euphoric Effects of Cocaine by the Dopamine D1/D5 Antagonist Ecopipam (SCH 39166)

  Archives of General Psychiatry · 1999 · 10.1001/archpsyc.56.12.1101

• The clinical pharmacology of ribavirin.

  PubMed · 1999

• Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine‐sensitive (es)‐nucleoside transporters

  British Journal of Pharmacology · 1998 · 10.1038/sj.bjp.0701775

• Ribavirin and interferon alfa‐2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

  British Journal of Clinical Pharmacology · 1998 · 10.1046/j.1365-2125.1998.00836.x

Current projects

No projects listed.